Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab for acute ischemic stroke infarct volume reduction
2013-001514-15Phase 2Completed
- Sponsor
- Biogen
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Natalizumab with Placebo (2 arms). Primary endpoint: Change in infarct volume from Baseline to Day 5. Started Aug 2013; status: completed.
02
Drugs
natalizumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2013-001514-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001514-15.